The roll call of therapeutic proteins includes some of biotechnology's most celebrated successes: clotting factors, anticoagulants, modern insulins, growth hormone, follicle-stimulating hormone, hematopoietic growth factors, interferons, and interleukins. The combined sales trend for therapeutic proteins-$34 billion in 2004 and projected to grow to $52.2 billion in 2010 1 -is testimony to their value in treating a wide range of serious diseases.
As patents on honored and famous proteins wind down, their owners naturally seek to protect their markets against interlopers. And in battles for market share going on today and battles to come, protein delivery technologies-the subject of this report-are major weapons of offense and defense. For if a therapeutic protein is bringing in big money and its patent is on the wane, someone somewhere with a clever technology is planning a market invasion based on improving how the protein is delivered. Protein delivery technologies are going to intensify competition in many markets. Thus, our report includes discussions of protein delivery technologies developed by:
• 19 companies targeting improved insulin delivery • 5 companies targeting improved erythropoietin delivery • 8 companies targeting improved interferon delivery • 6 companies targeting improved growth hormone delivery • 7 companies targeting improved parathyroid hormone delivery For some proteins and peptides, improving delivery may be essential in order to explore new indications. Here, protein delivery technologies can be tools for market expansion.
Trend #2: Noninjection technologies are beginning to deliver therapeutic proteins without needles
Transdermal, oral, pulmonary, and nasal delivery technologies are well established for small molecules. For therapeutic proteins, until recently they failed almost completely. The challenge for delivering proteins is to raise bioavailability from abysmal levels to at least 10%, and preferably much higher. Noninjection delivery technologies must also avoid pain and irritation and usually achieve rates of onset comparable to those with subcutaneous injections.
Chapters 4-6 discuss:
• 6 technologies for transdermal protein delivery • 5 technologies for oral protein delivery • 6 technologies for pulmonary protein delivery • 3 technologies for nasal protein delivery No one likes needles. We submit to them, though, because for some drugs there are no delivery alternatives. This is especially true for proteins. Almost every therapeutic protein is administered by intravenous, subcutaneous, or intramuscular injection. When frequent injections are required for treating chronic diseases, however, dislike of needles becomes a serious matter. For example, among diabetics it is documented that fear of needles causes many to delay insulin injections for years, at the risk of blindness, amputation and death. Better ways to deliver insulin are needed, and other therapeutic proteins as well. It is widely expected that noninjection protein delivery technologies will improve compliance and reduce complications arising from compliance failure. Because noninjection protein delivery is a young field, however, predictions diverge on how much compliance will improve. This can be seen in the figure below, which is part of a survey included with this report. Noninjection technologies must advance further before their effects on compliance are known. The most exciting news in noninjection protein delivery is the FDA approval in 2006 of Exubera, a dry powder aerosol technology for inhaled delivery of insulin. Exubera is a triumph, finally removing doubts that therapeutic proteins can be delivered by means other than injection. Now the question is, which other noninjection delivery routes will also work? Clinical trials should provide some answers within the next few years.
Exubera is so new that a number of important questions cannot yet be answered. One is the long-term safety of inhaling insulin. This, of course, will be closely watched. Another is how much Exubera will increase compliance to insulin therapy. Another regards the versatility of Exubera technology. Insulin is a rather small protein, around 5.8 kilodaltons. Can dry powder aerosol technology efficiently deliver much larger proteins? Answers await further investigations. In the meantime, we disagree with blanket dismissals that no noninjection technology can deliver larger proteins up to the size of antibodies (around 150 kilodaltons). We note, for instance, that one oral and pulmonary protein delivery technology described in this report is based upon a natural antibody transport mechanism and that the company behind this technology was recently acquired by one of the leading biotechnology companies. In our view, we would do well to avoid preconceptions and await the clinical data.
One thing these technologies will not do is banish injections altogether. Especially in hospital settings and for acute therapies, we expect therapeutic proteins will continue to be injected for years to come. That said, as more protein delivery technologies gain regulatory approval, we predict that patient and physician expectations will gradually change. If insulin can be delivered with an inhaler, why not other proteins, they may ask. This in turn will influence more companies developing therapeutic proteins to seriously consider noninjection delivery.
Will these Trends Merge?
Will therapeutic proteins with longer half-lives and other improvements eventually be delivered without injection? We believe that some will, once more of these technologies achieve regulatory approval. A few companies already participate in both technological trends and are in position to take early leads in this direction. Beyond this observation, many companies working on half-life extension may be only partially familiar with the capabilities of noninjection technology companies, and vice versa. Therefore, advantageous trendmerging technology combinations may exist that they are unaware of. Our hope is that the information in this report will help bring new technology partners together to mutual benefit.
Scope of this Report
Technologies discussed in this report are those most likely to affect the delivery of therapeutic proteins within the next 5 years. They are being tested today in clinical trials, or will be within a few years. They are not embryonic technologies under development in academic laboratories.
Technologies to enhance enzyme specific activity or improve binding affinity for receptors are not covered. These aspects of therapeutic protein function are not generally considered drug delivery characteristics.
This report also does not cover vaccine delivery, and with one exception does not cover delivery of monoclonal antibodies. Monoclonal antibodies are proteins, of course, but are generally considered a class unto themselves. Therapeutic proteins is a term often not intended to include monoclonal antibodies, and we have followed that convention here. The companies in this technology survey are not working on monoclonal antibody delivery. Regarding protein half-life extension, the main protein engineering subject in this report, monoclonal antibodies have very long half-lives compared to most proteins and are not generally believed to need further half-life enhancement. The exception is monoclonal antibody fragments that have lost the Fc domain. Antibody fragments have short half-lives that can be extended by technologies described herein. As for the noninjection technologies discussed in this report, they are not being developed expressly to deliver monoclonal antibodies, although some might be used for that purpose. 
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Introduction
Improving protein delivery by extending serum half-life is an intensely competitive area of protein engineering, engaging many companies with many approaches to the problem. And this is for good reason.
Extending the half-life of a proven protein with a soon-to-expire patent is a low-risk way to turn it once again into a marketplace home run. With the exception of monoclonal antibodies, which usually have serum half-lives of well over a week, most therapeutic proteins brought to market in the 1980s and 1990s had very short half-lives, just a few hours. For example, when used to treat chronic hepatitis C, interferon-α-2a (IFN-α-2a) and IFN-α-2b have half-lives of approximately 5 and 2.5 hours, respectively. 5 Their rapid elimination occurs primarily through kidney filtration.
Having a therapeutic effect with a short half-life protein usually calls for frequent and high dosing. For chronic hepatitis C, IFN-α-2a and IFN-α-2b are administered 3 times a week, subcutaneously or intramuscularly. High doses are necessary so that in spite of rapid protein elimination, there remains for several hours enough protein above the minimally effective concentration to exert a sustained therapeutic effect. Unfortunately, some therapeutic proteins have a narrow range between the minimum concentration required for efficacy and the maximum concentration for avoiding adverse effects. For these proteins, a high-and-frequent dosing schedule is likely to produce peak protein concentrations that are toxic. Thus, there is a great need for technologies that can deliver proteins in long-lasting doses that can be maintained within the protein's therapeutic index. The concentration curves in Figure 2 .1 illustrate the potential that extending protein halflife has for improving efficacy and safety and patient convenience. 
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PEGylated Interferons
PEGylated interferons illustrate what half-life extension technologies can achieve. PEGylation increases the half-lives of IFN-α-2a and IFN-α-2b approximately 15-fold. Consequently, to treat chronic hepatitis C, PEGylated interferons need only be administered once a week.
Half-life differs according to the route of administration; therapeutic protein half-lives will be different for intravenous and subcutaneous routes, for example. Besides route, primarily 4 factors determine the serum half-life of a therapeutic protein:
• Kidney filtration (for proteins smaller than 30 kilodaltons)
• Metabolism in the liver (for larger proteins)
• Degradation by proteolytic enzymes (proteases)
• Immunogenicity (protein neutralization by antibodies, and uptake by macrophages and dendritic cells)
Beginning with PEGylation, this chapter describes the technologies currently being used to extend therapeutic half-life. Most have not been around long enough to have taken extended half-life proteins completely through Phase III clinical trials. And the technologies that have received FDA approval-PEGylation, glycosylation, and one form of borrowing the half-life of albumin-continue to develop.
Increasing Half-life by PEGylation
In this report, PEGylation will refer to the covalent attachment of 1 or more high molecular-weight chains of polymerized polyethylene glycol (PEG) [CH 3 O-[CH 2 CH 2 O] n CH 2 CH 2 -OH] to a protein or peptide. In fact, other types of drugs can also be PEGylated; for instance, oligonucleotides. Here, however, only PEGylation of proteins or peptides will be discussed.
PEGylation, the oldest technology for protein half-life extension, was developed more than 20 years ago and proves how profitable half-life extension can be. Table 2 .2 lists 8 therapeutic proteins engineered for extended half-life. Six are PEGylation products, and their combined sales, according to PEGylation specialist Nektar Therapeutics (San Carlos, CA), is more than $5 billion annually. Clearly, PEGylation has set the pace in the race to bring extended half-life products to market.
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PEG comes in linear and branched chains and in standard molecular weights, typically 2000, 5000, 10,000, 20,000, and 40,000 kilodaltons. For protein delivery, sizes above 10,000 are the ones that are useful. PEGylation with large molecular-weight chains succeeds in part by masking a protein's antigenic determinants so that they are difficult for antibodies to recognize. It also succeeds because large PEG side chains increase effective protein size beyond the diameter renal glomerular capillaries, thereby blocking protein elimination through the kidneys. Thanks to reduced immunogenicity and kidney filtration, PEGylation increases protein half-life. Figure 2 .2 illustrates. An albumin-based technology probably applicable to all proteins; may be particularly helpful to proteins produced by microbial manufacture, because adding an affinity peptide increases molecular weight far less than adding the entire albumin protein
Source: CHI Advances Reports
Weaknesses:
Four days is the half-life upper limit thus far.
Threats:
Plenty of competition from other technologies
Opportunities:
Opens the door for more development of Fab monoclonal antibody fragments as therapeutics; may lower cost-of-goods-sold if manufactured with microbial expression systems
Increasing Half-life with the Streptococcal Albumin Binding Domain
The final albumin-based technology was developed by Affibody (Bromma, Sweden). The company is named after its products, Affibody molecules, which are antibody mimics derived from Protein A from Staphylococcus aureus.
Native Protein A is a S. aureus surface protein that binds the Fc domain of IgG antibodies. The tertiary structure of an Affibody molecule is 3 alpha helices derived from an Fc binding site of Protein A, as shown in Figure 2 .12. Of the 58 amino acids in this structure, 13 form the Fc binding site. Varying these 13 at random is the basis for creating an affinity ligand (Affibody molecule) library, which the company has used to screen for Affibody molecules that bind with high specificity and affinity to various antigens. For example, the company has isolated from its library an Affibody molecule that binds Her2, a receptor protein that, when overexpressed, is associated with an aggressive form of breast cancer. Dr. Abuchowski: I don't know of anyone doing it right now. It's too early. I think it probably can be done, but it adds another complication.
CHI: Can half-life extension help therapeutic proteins find new indications?
Dr. Abuchowski: Absolutely, because some proteins do not circulate long enough to be therapeutic in native form. Adenosine deaminase, for example, did not circulate long enough and could not be used as a therapeutic without PEGylation. A lot of cytokines may not be useful therapeutically because they don't circulate long enough. Many of the obesity peptides being developed don't circulate long enough; everybody is trying to PEGylate them. I venture to say that in the future more than half of all proteins introduced will be in PEGylated form. Almost every protein therapeutic that I know of that people are working on is being PEGylated.
CHI: What is the patent situation for PEG technology?
Dr. Abuchowski: The original patent on the concept has expired. Patents being generated currently relate to the chemistry of attaching PEG, the chemistry of the PEG itself, and specific product by process patents that relate to getting a superior product and the best yields.
CHI: So where do you see the field going from here?
Dr. Abuchowski: Believe it or not, I believe that even after 35 years this is just the beginning. The handful of products we have today is just the tip of the iceberg. Now everybody is trying to jump into it. There will even be a whole generation of PEGylated biogenerics-a biogeneric PEGASYS, a biogeneric PEG-Intron, a biogeneric Neulasta. The reality is that there are simply so many proteins out there in search of a pharmaceutical application that I can spend the rest of my career developing new PEG proteins.
